Key Takeaways:
- Q2 revenue of $243.7M beat consensus by $23.5M, up 120% year over year
- Attruby net product revenue jumped 211% to $222.4M as first-line share grew
- Three pipeline NDAs under FDA review with BBP-418 PDUFA set for Nov. 27
Geri
BridgeBio beats Q2 revenue as Attruby sales surge 211% to $222.4M
BridgeBio reported Q2 revenue of $243.7 million, beating consensus by $23.5 million as Attruby sales more than tripled year over year.
"This feels like we're at T equals zero in BridgeBio's next chapter," Chief Executive Neil Kumar said.
Attruby net product revenue rose to $222.4 million from $71.5 million a year earlier, a 211 percent jump. The company posted a loss of $0.78 a share, wider than the $0.60 forecast. Operating loss narrowed to $107.1 million from $134.3 million.
The results leave BridgeBio with $720.2 million in cash, plus about $1.7 billion pro forma after a $1 billion preferred equity financing closed July 1. Three pipeline programs are under FDA review, with BBP-418 for LGMD2I carrying a Nov. 27 PDUFA date.
Attruby, the treatment for ATTR cardiomyopathy, delivered a second straight quarter of sequential growth above $35 million. Royalty revenue climbed to $15.4 million from $1.6 million, helped by Beyonttra sales in Europe and Japan through partners Bayer and Alexion. License and services revenue fell to $5.8 million from $37.4 million, though last year's figure included a one-time $30 million regulatory milestone.
Kumar framed Attruby's trajectory as "Launch 2.0," citing new kidney-protective data published in Circulation: Heart Failure, real-world evidence showing a 37 percent reduction in composite cardiovascular events versus Pfizer's tafamidis at six months, and the failed CARDIO-TTRansform trial of eplontersen, which reinforced stabilizers as first-line standard of care. On pricing, he said, "We do not intend to chase anyone down the rabbit hole of trying to play near-term price dynamic games."
The pipeline has moved into regulatory review across all three late-stage programs. BBP-418 for LGMD2I received priority review with a Nov. 27 PDUFA date. Encaleret for ADH1 has a May 8, 2027 PDUFA date after priority review was granted in July. Infigratinib for achondroplasia has been submitted, with approval expected in mid-2027. The company also started Phase III work in chronic hypoparathyroidism, targeting a readout within 18 months.
Shares rose 1.26 percent in after-hours trading to $85.73, after closing the regular session at $84.67. The stock trades near the top of its 52-week range of $46.29 to $93.42 and has delivered an 82 percent return over the past year. Wall Street maintains a Strong Buy consensus with price targets ranging from $80 to $157.
The revenue beat and cash position support three potential launches over the next 12 months, but the EPS miss reflects the cost of building a multi-product rare-disease company. Investors will watch the Oct. 8 Commercial Day in New York for deeper detail on launch readiness across the three pipeline programs.
This article is for informational purposes only and does not constitute investment advice.
[1] BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge[2] Earnings call transcript: BridgeBio beats revenue in Q2 2026 as Attruby surges[3] BRIDGEBIO PHARMA ($BBIO) Releases Q2 2026 Earnings | Quiver Quantitative[4] Is BridgeBio Pharma Inc (BBIO) Undervalued After Q2 Earnings Beat? Revenue of $243.7M Surpasses Estimates, GF Score: 69/100[5] BridgeBio Pharma posts higher Q2 2026 revenue, ongoing losses | BBIO Quarterly Report (10-Q)
